Nautilus Biotechnology, Inc. — Director's Dealing 2021

Dec 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-11-30

Reporting Person: Patel Sujal M (Director, CEO, President, and Secretary, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-30	Common Stock	P	161978	$4.7215	Acquired	9776366	Direct
2021-12-01	Common Stock	P	88022	$4.7306	Acquired	9864388	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5280476	Indirect
Common Stock	1814035	Indirect

Footnotes

F1: Represents the weighted average share price of an aggregate total of 161,978 shares purchased in the price range of $4.48 to $4.85 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average share price of an aggregate total of 88,022 shares purchased in the price range of $4.44 to $5.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.

F4: Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.